Bal Pharma (BALPHARMA)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 19.88% shows good demand traction.
• Profit growth of 270.83% indicates a sharp earnings recovery, albeit from a low base.
• Piotroski F-Score of 7/9 suggests improving financial health.
• Promoter holding of 50.86% gives reasonable owner alignment.
• Valuation is moderate at P/E 14.76 and P/B 1.16, with a 1.59% dividend yield.

Concerns

• Debt/Equity of 1.98 is high, making the balance sheet leveraged.
• ROE of 8.11% and ROCE of 10.10% are modest, well below quality-compounder standards.
• Latest quarter net profit of ₹2 Cr on sales of ₹88 Cr implies a thin ~2.3% net margin.
• Profit growth of 270.83% is likely a low-base effect and not a dependable annual rate.

AI Analysis

Bal Pharma is the kind of stock that makes me apply both lenses: quality and price. At ₹78.45, market cap ₹120 Cr, the market is paying 14.76 times earnings and just 1.16 times book value. That is not an expensive price for a pharmaceutical business. But cheapness alone is never enough. I need a business that can earn a decent return on equity without drowning in debt. Here, ROE is only 8.11% and ROCE 10.10%, while debt-to-equity stands at 1.98. That leverage bothers me. A company that borrows heavily to generate single-digit returns is not compounding shareholder wealth with a margin of safety. The latest quarter shows sales of ₹88 Cr and net profit of only ₹2 Cr — a thin margin. Profit growth of 270.83% sounds remarkable, but it is off a low base; sales growth of nearly 20% is more useful as an indicator. The Piotroski score of 7/9 suggests financial health has improved, and promoter holding of 50.86% aligns interests. Dividend yield of 1.59% is modest. PEG of 0.10 is almost too good to be true, and that makes me suspicious rather than excited. In Graham's language, I want a defensive investment: adequate financial strength, stable earnings, and reasonable valuation. Bal Pharma has some value, but the high debt and thin margins keep me from calling it a great business. I would need several years of consistent, debt-reduced performance before I could sleep well owning it. For now, it is an interesting small-cap pharma, not a Buffett-quality compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer